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The objective of this retrospective cohort study is to assess the mechanism by which human immunodeficiency virus
type 1 (HIV) influences hepatitis C virus (HCV) replication in injecting drug users. Virological (HCV and HIV RNA levels)
and immunological (CD41, CD81 cell counts, and anti-CD3 reactivity) parameters were determined in 19 HCV sero-
converters in sequential samples over a period of 1 to 9 years. Among these subjects, 10 were HIV-seronegative
(HIVneg), 4 were HIV-seropositive (HIVpos), and 5 seroconverted for HIV (HIVsc) during the observation period. HCV
RNA levels were higher in HIVpos subjects than in HIVneg subjects. In subjects seroconverting for HIV, HCV RNA levels
increased significantly immediately after HIV seroconversion (P , 0.0001), while they remained stable over time in
HIVpos and HIVneg subjects. HCV RNA correlated inversely with CD41 cell counts in both the HIVpos population (R 5
20.22, P , 0.05) and the HIVneg population (R 5 20.45, P , 0.0001). In addition, when subjects were stratified
according to CD41 cell counts a significant difference was found in HCV RNA levels between HIVpos and HIVneg
subjects with CD41 cell counts .500 cells/ml (P 5 0.001), but not in the population with CD41 cell counts ,500 cells/ml.
In no population was a correlation found between HCV RNA levels and CD81 cell counts or anti-CD3 reactivity. Both HIV
infection and CD41 cell counts are apparently associated with HCV RNA levels. The direct association, independent of
CD41 cell counts, between HIV infection and HCV replication appears to be stronger than the association between
HIV-induced CD41 cell decline and HCV replication. We conclude that (i) HCV replication is in some way directly
influenced by the presence of HIV; (ii) HCV-specific host immunity controls, in part, HCV replication; and (iii) HCV
replication increases when the immune system is impaired by HIV. © 1998 Academic Press
INTRODUCTION
Hepatitis C virus (HCV) is a major cause of parenter-
ally transmitted acute hepatitis (Choo et al., 1989) and is
widespread among injecting drug users, with up to 90%
being positive for antibodies to HCV (van den Hoek et al.,
1990; Thomas et al., 1995). The clinical manifestations of
HCV infection are diverse, and the clinical course is
difficult to predict. Commonly, the course of HCV infec-
tion remains benign in the first few years (Eyster et al.,
1993), although the majority (.80%) of HCV-infected in-
dividuals develop chronic disease and some may even-
tually progress to liver diseases, like liver fibrosis, cir-
rhosis, and hepatocellular carcinoma (Alter et al., 1992;
Saito et al., 1990; De Mitri et al., 1995; Esteban, 1993). The
natural history of HCV is poorly understood, especially
the degree to which hepatocellular damage is mediated
by the immune system or by the direct pathogenicity of
HCV. HCV seems to show a higher replication rate in
patients receiving immunosuppressive therapy and in
patients co-infected with HIV (Sherman et al., 1993; Ey-
ster et al., 1994; Cribier et al., 1995). Since HCV and HIV
share the same parenteral route of transmission, co-
infections with HCV and HIV are frequently found in
injecting drug users (van den Hoek et al., 1990; Thomas
et al., 1995) and in hemophiliacs who received multiple
transfusions with clotting factor concentrates before
1985 (Eyster et al., 1993; Cribier et al., 1995; Watson et al.,
1992).
HIV is known to cause immunosuppression character-
ized by a decline in CD41 cell counts that is followed by
clinical manifestations of acquired immunodeficiency
syndrome (AIDS). Several reports have suggested that
HCV replication is enhanced by HIV infection, either by
HIV-induced immunosuppression or by HIV–HCV inter-
action (Thomas et al., 1996; Ghany et al., 1996; Chambost
et al., 1995; Sherman et al., 1993; Eyster et al., 1994;
Cribier et al., 1995); however, an association between
HCV RNA levels and CD41 cell counts in HIV-seroneg-
ative individuals remains to be demonstrated. In this
study three immunological markers (CD41, CD81 cell
counts, and anti-CD3 reactivity) were compared with
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HCV and HIV RNA levels in serial time points among 19
HCV seroconverters.
RESULTS
Impact of HIV infection on HCV RNA level
To determine the influence of HIV infection on HCV
replication, we compared serial measurements of HCV
RNA in subjects who remained HIV negative (HIVneg),
were HIV positive (HIVpos), or seroconverted for HIV
during the study period. None of the subjects were
treated with any antiviral therapy.
HCV RNA levels were measured at 355 datapoints by
the bDNA and at 130 datapoints with NASBA. The HCV
NASBA was additionally used to study the concordance
between the two assays and a significant association
between the two quantitative HCV RNA assays was
found when all values below the lower limit of both
assays were omitted (R 5 0.81, P , 0.0001; Fig. 1).
HCV RNA levels appeared to be higher among HIVpos
subjects than among HIVneg subjects. This same phe-
nomenon was observed among subjects who serocon-
verted for HIV: lower HCV RNA levels during the pre-HIV
seroconversion period and higher levels after HIVsc
(Fig. 2). To certify if the influence of HIV infection on HCV
RNA replication was statistically significant, log-trans-
formed HCV RNA copies were compared in HIVneg and
HIVpos subjects. Over the whole observation period,
mean HCV RNA levels within the HIVneg population
were 105.62 6 0.73 HCV RNA copies/ml, and within the
HIVpos population 106.70 6 0.84 HCV RNA copies/ml (P ,
0.0001). Comparing the mean HCV RNA levels among the
HIV seroconverters before (Fig. 3, left bar) and after (Fig.
3, right bar) HIVsc, HCV RNA levels increased from
10
5.43 6 0.66
to 106.72 6 0.81 HCV RNA copies/ml (P , 0.0001;
Fig. 3). To determine whether this increase was due to
HIV infection per se and not to the duration of HCV
infection, we divided the mean study period of the
HIVneg and HIVpos population into two equal parts, with
a mean duration of approximately 2.5 years in both pop-
ulations. Similarly, among the HIV serocoverters, we
found that the mean period prior to HIV seroconversion
was 2.4 years, whereas the mean period after HIV sero-
conversion was 1.9 years. No differences were found in
HCV RNA levels between the first (Fig. 3, left bar) and
second (Fig. 3, right bar) period of 2.5 years among the
HIVneg and HIVpos subjects, indicating that the duration
of HCV infection was not influencing HCV replication
during the first 5 years of HCV infection. Mean HCV RNA
levels were lower among HIVneg subjects than among
HIVpos subjects, during both the first and the second
period of 2.5 years (P , 0.0001). Moreover, comparing
HCV RNA levels among HIV seroconverters before HIVsc
with the levels among HIVneg subjects, levels of HCV
RNA were indistinguishable (P . 0.1). On the other hand,
HCV RNA levels were significantly higher after HIVsc
(P , 0.0001), but indistinguishable from HIVpos (P . 0.1).
Using all datapoints above the lower limit of the quan-
tification assay for both HIV RNA and HCV RNA concen-
trations, no significant association was found between
parameters (R 5 0.06, P 5 0.60; Fig. 4). This lack of
association between parameters might indicate that HIV
FIG. 1. Relation between HCV RNA levels as measured by bDNA and NASBA. The linear regression line is shown (R 5 0.81, P , 0.0001).
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(or HIV proteins) enhances HCV replication when a cer-
tain threshold of HIV replication is reached.
Impact of immunological parameters on HCV RNA
levels
To address the relationship between HCV RNA levels
and CD41, CD81 cell counts and anti-CD3 reactivity, we
used serial measurements of all parameters in 19 HCV
seroconverters that remained HIVneg (n 5 10), serocon-
verted for HIV (n 5 5), or were HIVpos prior to HCVsc (n 5
4). There were 292 samples that could be analyzed two-
sided for the relationship between HCV RNA levels and
CD41 and CD81 cell counts, as well as 233 samples with
anti-CD3 reactivity. Only values above the detection limit of
the bDNA assay were used in regression analyses of HCV
RNA levels and immunological parameters.
The CD41 cell counts and HCV RNA levels were sig-
nificantly associated across the entire study population
(R 5 20.52, P , 0.0001; Fig. 5a). To address if this
association was solely due to an HIV-induced decline in
CD4 cell counts, we set aside a HIVneg population and
a HIVpos population. The association of CD41 cell
counts and HCV RNA levels was also significant in the
HIVneg population (R 5 20.45, P , 0.0001; Fig. 5b). A
weaker correlation was found between CD41 cell counts
and HCV RNA levels in the HIVpos population (R 5
20.22, P , 0.05; Fig. 5c).
No correlation was found, either across the whole
population or in the two separated populations, between
HCV RNA and CD81 cell counts or the anti-CD3 reactivity
(P . 0.1; results not shown).
Influence of HIV infection on HCV RNA levels in
populations stratified according to CD41 cell counts
To obtain evidence of HIV infection influencing HCV
RNA levels, independently of CD41 cell counts, we sep-
arated the 19 subjects into three groups: those whose
CD41 cell counts were low (400–500 cells/ml), interme-
FIG. 2. Comparison of serial measurements of HCV RNA levels among a HIV negative subject, a HIV positive subject, and a HIV seroconverter.
The dotted line represents the detection limit of the bDNA assay.
FIG. 3. Comparison of HCV RNA levels among HIVneg, HIVsc, and
HIVpos subjects. The left and right bars in the HIV seroconverters
represent data of mean values of HCV RNA measured before and after
HIV seroconversion, respectively, whereas the left and right bars in
both the HIVneg and the HIVpos populations represents data of mean
values of HCV RNA measured in the first and second 2.5 years of HCV
infection, respectively, as described under Results.
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diate (500–900 cells/ml), and relatively high (900–1300
cells/ml). These particular strata were made because
none of the HIVneg individuals had a CD41 cell count
below 400 cells/ml, and in addition none of the HIVpos
individuals had CD41 cell counts greater than 1300 cells/
ml. HCV RNA levels could thus be studied in groups of
HIVneg and HIVpos subjects with comparable CD41 cell
counts. Despite the fact that no significant difference in
CD41 cell counts between the HIVneg and the HIVpos
populations was found within strata, there was a signif-
icant difference in HCV RNA levels between the HIVneg
and the HIVpos populations in both the intermediate and
the high CD41 cell counts group. In the low CD41 cell
counts group the same trend was observed, although the
difference was not significant (Table 1).
DISCUSSION
Co-infections with HCV and HIV often occur in inject-
ing drug users (van den Hoek et al., 1990; Thomas et al.,
1995), and in multitransfused hemophiliacs treated with
clotting factor concentrates before 1985, when HCV was
not yet discovered or isolated and HIV testing was intro-
duced (Eyster et al., 1993; Cribier et al., 1995; Watson et
al., 1992). Interactions between HCV and HIV have been
studied, but with some conflicting results. Most studies
have found increased HCV RNA levels in subjects who
seroconverted for HIV, without a correlation with CD41
cell counts, suggesting that HIV infection affects the
replication of HCV (Cribier et al., 1995; Eyster et al., 1994;
Sherman et al., 1993; Telfer et al., 1994; Thomas et al.,
1996). However, whether increased HCV replication is
directly influenced by the infection with HIV in itself or
indirectly mediated by the immune system remains un-
clear. Eyster et al. (1994) reported a 58-fold increase in
HCV RNA levels in subjects who became HIVpos and a
strong association between HCV RNA levels and CD41
cell counts among HIVpos hemophiliacs. This latter as-
sociation, however, was strongly influenced by values of
23 samples taken at least 2 years after HIV seroconver-
sion. In a prospective study of HIVsc among injecting
drug users, Thomas et al. (1996) found significantly lower
HCV RNA levels before HIV seroconversion. They also
found an association of CD41 cell counts and HCV RNA
levels, although this was related to the time from HIV
seroconversion. Ghany et al. (1996) reported that levels
of HCV RNA among HIVneg hemophiliacs were similar to
levels among those who were HIVpos, suggesting that
HIV infection is not the only factor that influences HCV
replication. They found higher HCV RNA levels in sub-
jects with severe immunodeficiency, i.e., those having
CD41 cell counts below 200 cells/ml. The lack of asso-
ciation between CD41 cell counts and HCV RNA levels
in some reports might reflect a deficit of serial measure-
ments or sampling bias, of both HCV RNA levels and
immunological parameters, and/or a lack of measure-
ments taken before and after HIV seroconversion.
In our study, the impact of HIV infection and HIV-
induced immunodeficiency was assessed by comparing
FIG. 4. Association between HCV RNA and HIV RNA levels. The linear regression line is shown (R 5 0.06, P 5 0.60). The dotted line represents
the detection limit of both assays.
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three immunological markers with HCV and HIV RNA
levels as measured on serial samples of 19 HCVsc who
were HIVneg, HIVsc, or HIVpos. HIV infection influenced
the HCV replication rate significantly when HIVneg and
HIVpos populations were compared in different strata of
CD41 cell counts above 500 cells/ml. This indicates that
HIV infection per se, in an individual with a normal
immune status, directly enhances the HCV replication
level. The same was seen in HIV seroconverters, in
whom HCV RNA levels were significantly higher after HIV
seroconversion. Mean HCV RNA levels did not change
significantly from the beginning of HCV infection to the
FIG. 5. Association between HCV RNA levels and CD41 cell counts. The linear regression lines are shown. (a) Among the whole population (R 5
20.52, P , 0.0001). (b) Among the HIVneg population (R 5 20.45, P , 0.0001). (c) Among the HIVpos population (R 5 20.22, P , 0.05). The dotted
line represents the detection limit of the bDNA assay.
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end of follow-up among individuals who remained
HIVneg, or among individuals who were HIVpos at entry.
One study found that, regardless of HIV status, HCV RNA
levels were affected by the duration of HCV infection,
although not very significant (Eyster et al., 1994). In our
study no association was found between HCV RNA lev-
els and duration of HCV infection, possibly because the
mean follow-up in our study was only 5.4 years, while
others found this correlation over the next 5 to 12 years
or more.
No significant association was found between HCV
RNA and HIV RNA levels when values below the lower
limit of the bDNA assay were omitted in the regression
analysis, which corroborates the results of Cribier et al.
(1995). From our quantitative HCV and HIV data one
might conclude that a minimal level of HIV replication is
needed for the up-regulation of HCV replication. How-
ever, more HIV replication does not apparently lead to
more HCV replication, suggesting that when a threshold
of HIV replication is achieved, HCV replication is inde-
pendent of HIV replication.
To assess the degree of immunological control for
HCV replication, CD41 and CD81 cell counts and anti-
CD3 reactivity were studied as surrogate markers for
HCV-specific immunity in the whole population and in the
separated groups according to HIV status. CD41 cell
counts and HCV RNA levels were strongly associated
across the whole study population. This suggests that a
decline of CD41 cell counts, as a surrogate marker for
HCV-specific immunity, increases HCV replication. To
TABLE 1
Analysis of HIV Status and CD41 Cell Counts in Relation to HCV RNA Load
n Mean HCV RNA 6 SD P Mean CD41 cells 6 SD P
CD41 400–500 cells/ml
HIVneg 9 6.328 6 .862 NS 467 6 30 NS
HIVpos 10 6.758 6 .945 442 6 29
CD41 500–900 cells/ml
HIVneg 79 5.953 6 .881 0.001 732 6 124 NS
HIVpos 29 6.572 6 .782 690 6 103
CD41 900–1300 cells/ml
HIVneg 80 5.373 6 .538 0.0001 1098 6 118 NS
HIVpos 7 6.772 6 1.110 1089 6 114
Note. NS, not significant.
FIG. 5—Continued
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determine if this correlation was confounded by HIV
infection, the association of CD41 cell counts and HCV
RNA levels in serial samples from the HIVneg population
was studied. The inverse relationship between CD41
cell counts and HCV RNA levels suggests even more that
propagation of HCV is dependent on the quality of the
immune system, implying that HCV replication is at least
partially under the control of the immune system. In other
words, when HCV-specific immune responses deterio-
rate, the level of HCV replication might increase. This will
then be expressed in elevated HCV RNA levels, which
are possibly accumulating over time among HIVneg in-
dividuals as has been previously suggested (Eyster et
al., 1994). No significant association was found between
HCV RNA and CD81 cell counts. These data corroborate
an earlier observation that HCV-specific CD81 CTL re-
sponses do not exert much control over HCV (Reher-
mann et al., 1996), whereas HCV-specific CD41 T-cell
responses seem to be able to control HCV propagation
by maintaining humoral responses and probably there-
fore play a more important role in the elimination of HCV
infection (Missale et al., 1996; Botarelli et al., 1993;
Diepolder et al., 1995). Conversely, the decline in the
number of HCV-specific CD41 T-cell responses may lead
to increased HCV RNA levels. HCV RNA levels among
HIVpos subjects were also significantly associated with
CD41 cell counts but less powerfully, most likely be-
cause they all had relatively low CD41 cell counts due to
HIV infection, with a relatively wide range in HCV RNA
levels.
The effect of HIV infection on HCV RNA levels, inde-
pendent of CD41 cell counts, was shown across the
whole population, divided in three groups according to
their CD41 cell counts. Significantly increased HCV RNA
levels related to HIV seropositivity were found in the two
groups with intermediate and high CD41 cell counts,
suggesting the direct role of HIV infection on the repli-
cation rate of HCV. In the group with CD41 cell counts
between 400 and 500 cells/ml, more or less the same
phenomenon was observed: higher HCV RNA levels
among the HIVpos population with comparable CD41
cell counts. However, these higher HCV RNA levels were
not significantly different, probably because of the small
number of individuals present in this group compared
with the other two groups. The mechanism for this direct
regulation is still unclear, but it has been described that
the liver, the primary HCV reservoir, contains the largest
population of macrophages, the so-called Kupffer cells,
and the presence of HIV was demonstrated in Kupffer
cells and hepatocytes in AIDS patients by several groups
(Hufert et al., 1993; Housset et al., 1993; Cao et al., 1992).
The HIV tat gene is a potent transactivator, capable of
up-regulating viral gene expression in cultured cells by
both transcriptional and posttranscriptional mecha-
nisms, and has been shown to induce dermal lesions
which resemble Kaposi’s sarcoma in transgenic mice
(Vogel et al., 1988). Recently, a putative tat-binding motif
was found in the gene coding for the NS4 protein of HCV,
and it was assumed that the HIV tat protein may modu-
late HCV infections by directly up-regulating HCV repli-
cation (Ferbeyre et al., 1997). Although this assumption
was not addressed by us and further studies are needed,
it might be a possible explanation for the direct effect of
HIV on the replication rate of HCV, provided that most
HCV-infected cells are co-infected with HIV.
In summary, our data indicate that: (i) HIV infection
leads to enhanced HCV replication; (ii) an inverse rela-
tionship between CD41 cell counts and HCV RNA levels
is seen in HIV infected individuals; and (iii) there is an
inverse relationship between CD41 cell counts and HCV
RNA levels among HIVneg individuals, suggesting that
HCV replication is under the control of the immune sys-
tem. Therefore we conclude that HIV influences HCV
replication in two ways (Fig. 6). HCV replication is in
some way directly influenced by HIV and HIV may reduce
the HCV-specific immunity by impairment of the overall
immune response.
PATIENTS AND METHODS
Participants
The injecting drug users were recruited from a cohort
started in December 1985 (van den Hoek et al., 1988),
consisting of drug users living in Amsterdam and partic-
ipating in the Amsterdam Cohort Studies on HIV and
AIDS. In March 1996, we selected individuals who were
followed for at least 3 years and seen at least seven
times (n 5 358). Their serum and plasma samples were
stored initially at 14°C, then frozen at 220°C within 24 h
of collection and handling, and ultimately stored at
270°C. Among 358 subjects, 19 HCV seroconverters
were identified (Beld et al., 1998) and divided into three
groups on the basis of their HIV status: (i) HIVneg
throughout the study period (n 5 10); (ii) HIVsc during the
study (n 5 5); (iii) HIVpos before HCVsc (n 5 4). HCV
RNA load was determined on every single sample for
which the immunological data were available (n 5 294).
The average sampling interval between samples con-
taining both data was 5 months (range 0.5–48 months),
FIG. 6. Schematic representation of the direct association of HIV
infection and the HIV-induced CD41 cell count decline on HCV RNA
levels. The thickness of the arrows represents the strength of the
association.
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with an average of 15 time-points per patient (range 2–22
time-points). The mean follow-up of HCV infection was
5.4 years (range 1–9 years), whereas the mean follow-up
of HIV infection was 3.5 years (range 1–7 years). None of
the 19 subjects received antiretroviral therapy during
follow-up.
Serological data
Sera were tested for the presence of antibodies to
HCV by the third-generation Enzyme Immunoassay (EIA
3.0; Abbott Laboratories, Chicago, IL). All positive EIA 3.0
assays were confirmed by the third-generation Strip Im-
munoblot Assay (SIA, RIBA, Chiron Corp., Emeryville,
CA). Antibodies to HIV-1 were determined with commer-
cial Enzyme Immunoassay (EIA; Abbott Laboratories)
and confirmed by Western blot (Diagnostic Biotechnol-
ogy, Herent, Belgium). All serological assays were per-
formed according to the manufacturer’s manual.
Viral RNA quantification
The HCV RNA load was determined longitudinally in
the 19 HCV seroconverters, on 355 available samples by
the branched DNA (bDNA) signal amplification assay 2.0
(Quantiplex HCV RNA, Chiron Corp.). All samples were
tested in duplicate, and the mean value of the duplicate
tests was used for data analysis. Viral load, expressed
as HCV RNA copies/ml, was determined by comparison
with an external standard curve with a quantitation limit
of 2.0 3 105 HCV RNA copies/ml. A subset of samples
(n 5 130) representing all 19 HCV seroconverters was
quantified by a prototype HCV NASBA (with reagents
kindly provided by P. Sillekens and T. Kievits of Organon
Technica, Boxtel, The Netherlands). The NASBA method
(Gemen van et al., 1994; Jurriaans et al., 1995; Kievits et
al., 1991) amplifies the isolated nucleic acids under iso-
thermal conditions using three enzymes simultaneously;
reverse transcriptase, RNase H, and a DNA-dependent
RNA polymerase. Briefly, the reaction starts with hybrid-
ization of one of the oligonucleotide primers, containing
a T7 promotor, to the target RNA followed by elongation
of the primer by reverse transcriptase. The RNA strand in
the resulting RNA/DNA hybrid is then degraded by the
activity of RNase H, which enables the annealing of the
second oligonucleotide primer to the single-stranded
cDNA. Next, a second DNA strand is synthesized by the
DNA-dependent DNA polymerase of reverse transcrip-
tase, yielding a double-stranded DNA molecule with a T7
RNA polymerase sequence. The T7 RNA polymerase can
produce 100–1000 RNA copies from each double-
stranded DNA molecule. Each RNA molecule synthe-
sized can serve as a template in new rounds of cDNA
and subsequent RNA synthesis. Viral load, expressed as
RNA copies/ml, was determined using electrochemilu-
minescence and by comparison with an internal stan-
dard curve with a quantification limit of 4.0 3 103 HCV
RNA copies/ml. HIV RNA load was also determined by
the NASBA technology, which has a quantification limit of
103 HIV RNA copies/ml. All quantification assays were
performed according to the manufacturer’s manual.
T-cell subsets and T-cell reactivity
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized venous blood by density–gradient
centrifugation on Ficoll–Hypaque (Pharmacia, Uppsala,
Sweden). T lymphocyte immunophenotyping for CD4 and
CD8 membrane markers was performed on a Coulter
Epics-C cytofluorometer (Coulter Electronics, Hialeah,
FL). PBMC were stained with CD4-mAb (Leu-3a-PE; Bec-
ton Dickinson, Mountain View, CA) or CD8-mAb (Leu-2a-
PE; Becton Dickinson) according to the manufacturer’s
protocols. T-cell responsiveness was measured in tripli-
cate as previously described (Schellekens et al., 1990),
by measuring CD3-mAb (CLB, Amsterdam, The Nether-
lands)-induced proliferative capacity of PBMC in whole-
blood cultures. The anti-CD3 response is given as
counts per minute.
Statistical methods
Scatterplots were used to review the distributions of
HCV RNA and HIV RNA, respectively, with all immuno-
logical markers. For statistical analysis, we used log-
transformed viral RNA concentrations. The regression
analyses were performed only with data above the de-
tection limit of the quantification assays and values be-
low the detection limit were omitted. The Mann–Whitney
test was used for comparison of groups. A value of P ,
0.05 was considered significant.
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